Stoke's Q2 Losses Widen Amid Increased R&D Spend

TL;DR

**Stoke's cash burn is accelerating, putting pressure on zorevunersen's clinical progress to justify the mounting losses.**

AI Summary

Stoke Therapeutics, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The net loss for the three months ended June 30, 2025, was $48.2 million, an increase from a net loss of $44.1 million for the same period in 2024. For the six months ended June 30, 2025, the net loss was $95.5 million, up from $86.5 million in 2024. Research and development expenses increased to $40.5 million for the three months ended June 30, 2025, from $36.6 million in 2024, primarily due to increased external program costs for their lead product candidate, zorevunersen, and other programs. General and administrative expenses also rose to $8.2 million from $7.6 million in the comparable 2024 period. The company's cash, cash equivalents, and marketable securities totaled $267.5 million as of June 30, 2025, down from $316.5 million at December 31, 2024, indicating a burn rate of approximately $49 million in the first half of 2025. Stoke Therapeutics continues to focus on advancing its pipeline, particularly zorevunersen for Dravet syndrome, and managing its cash runway.

Why It Matters

For investors, Stoke's widening net loss and increased R&D expenses highlight the significant capital requirements of drug development, especially for a company with no current revenue. The cash burn rate of $49 million in the first half of 2025 is a critical metric, indicating the company's runway and potential need for future financing. Employees face continued pressure to deliver on clinical milestones, particularly for zorevunersen, to justify ongoing investment. Customers, specifically patients with Dravet syndrome, are awaiting the successful development of zorevunersen, making clinical trial progress paramount. In the competitive landscape of rare disease therapeutics, Stoke's ability to efficiently advance its pipeline against larger pharmaceutical players is crucial for long-term viability.

Risk Assessment

Risk Level: high — The risk level is high due to the company's pre-revenue status and increasing net losses, which reached $95.5 million for the six months ended June 30, 2025. The cash, cash equivalents, and marketable securities decreased by $49 million to $267.5 million from December 31, 2024, indicating a significant burn rate without a clear path to profitability in the near term. This financial position, coupled with the inherent risks of clinical drug development, presents substantial uncertainty.

Analyst Insight

Investors should closely monitor the clinical trial progress of zorevunersen and other pipeline candidates, as these are the primary value drivers. Evaluate the company's cash runway against its projected R&D spend to assess the likelihood of future dilution. Consider this a high-risk, high-reward investment suitable for those with a strong understanding of biotech development cycles and a high tolerance for risk.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$48.2M

eps

N/A

gross Margin

N/A

cash Position

$267.5M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the three and six months ended June 30, 2025, indicating pre-commercial stage)
• $48.2M — Net Loss (for the three months ended June 30, 2025, an increase from $44.1M in 2024)
• $95.5M — Net Loss (for the six months ended June 30, 2025, an increase from $86.5M in 2024)
• $40.5M — Research and Development Expenses (for the three months ended June 30, 2025, up from $36.6M in 2024)
• $267.5M — Cash, Cash Equivalents, and Marketable Securities (as of June 30, 2025, down from $316.5M at December 31, 2024)
• $49M — Cash Burn (for the first six months of 2025)

Key Players & Entities

• Stoke Therapeutics, Inc. (company) — filer of the 10-Q
• zorevunersen (product) — lead product candidate for Dravet syndrome
• Dravet syndrome (medical_condition) — target indication for zorevunersen
• Acadia Pharmaceuticals Inc. (company) — collaboration partner mentioned in the filing
• Biogen (company) — license agreement partner

FAQ

Risk Factors

• Sustained Net Losses and Cash Burn [high — financial]: Stoke Therapeutics reported a net loss of $48.2 million for Q2 2025, an increase from $44.1 million in Q2 2024. The first half of 2025 saw a net loss of $95.5 million. The company's cash, cash equivalents, and marketable securities decreased to $267.5 million as of June 30, 2025, from $316.5 million at the end of 2024, indicating a burn rate of approximately $49 million in the first half of 2025. This trend necessitates continued access to capital to fund operations.
• Dependence on Lead Product Candidate [high — operational]: The company's primary focus is on advancing zorevunersen for Dravet syndrome. Success is heavily reliant on the clinical development, regulatory approval, and eventual commercialization of this single product candidate. Any setbacks in its development or approval process could significantly impact the company's future.
• Drug Development and Approval Risks [high — regulatory]: As a biotechnology company, Stoke Therapeutics faces inherent risks associated with the lengthy, complex, and expensive process of drug development, including clinical trials and regulatory approvals from bodies like the FDA. Failure to demonstrate safety and efficacy in clinical trials or obtain regulatory approval for zorevunersen or other pipeline candidates would severely impact the business.
• Limited Operating History and No Revenue [medium — financial]: Stoke Therapeutics has no history of generating revenue, as it is in a pre-commercial stage. Its financial performance is entirely dependent on its ability to secure funding and successfully bring its drug candidates to market. The lack of revenue means the company is not yet self-sustaining.
• Reliance on External Collaborations and Third Parties [medium — operational]: The company relies on external program costs and potentially third-party manufacturers for its product candidates. Any disruptions or issues with these external relationships, including the Biogen License Agreement, could affect the timely development and supply of its therapies.

Industry Context

The biotechnology sector, particularly companies focused on rare diseases and neurological disorders, is characterized by high R&D investment and significant regulatory hurdles. Stoke Therapeutics operates in this environment, competing for capital and talent with other firms pursuing novel therapeutic approaches. The success of gene-silencing therapies and precision medicine is a key trend, but clinical and commercial success remains challenging.

Regulatory Implications

Stoke Therapeutics is subject to stringent regulatory oversight from agencies like the FDA. The development and approval process for zorevunersen is critical. Any delays, adverse findings in clinical trials, or failure to meet regulatory standards could halt development and significantly impact the company's viability.

What Investors Should Do

1. Monitor R&D Spend and Pipeline Progress
2. Assess Cash Runway and Future Financing Needs
3. Evaluate Competitive Landscape and Market Potential

Key Dates

• 2025-06-30: Quarterly Report (10-Q) Filing — Provides updated financial and operational information for the period ending June 30, 2025, including net loss, R&D expenses, and cash position.
• 2025-06-30: End of Second Quarter 2025 — Marks the end of the reporting period for the 10-Q, with key financial metrics like cash reserves and burn rate being assessed as of this date.
• 2025-04-01: Start of Second Quarter 2025 — Beginning of the period for which R&D and G&A expenses are detailed in the 10-Q.
• 2024-06-30: End of Second Quarter 2024 — Provides a comparative period for Q2 2025 financial results, highlighting increases in net loss and R&D expenses.
• 2024-12-31: End of Fiscal Year 2024 — Provides the prior year-end cash position for comparison with the current period's cash reserves.

Glossary

Zorevunersen

Stoke Therapeutics' lead product candidate, a therapy designed to treat Dravet syndrome. (Central to the company's development pipeline and future revenue potential.)

Dravet Syndrome

A rare, severe form of epilepsy that begins in infancy. (The target indication for Stoke's lead drug candidate, zorevunersen.)

Pre-commercial stage

A phase in a biotechnology or pharmaceutical company's lifecycle where it has not yet received regulatory approval for any of its products and therefore has no revenue from product sales. (Explains why Stoke Therapeutics reports zero revenue and relies on funding for operations.)

Cash Burn Rate

The rate at which a company spends its cash reserves, typically used for companies that are not yet profitable. (Indicates the speed at which Stoke Therapeutics is depleting its cash, highlighting the need for careful financial management and potential future financing.)

Research and Development (R&D) Expenses

Costs incurred by a company in the process of developing new products or improving existing ones, including clinical trials, research personnel, and external program costs. (A significant expense for Stoke Therapeutics, reflecting investment in its pipeline, particularly zorevunersen.)

Marketable Securities

Investments that are readily convertible into cash, such as stocks, bonds, and other financial instruments. (Part of Stoke's liquid assets, contributing to its overall cash position and ability to fund operations.)

Year-Over-Year Comparison

Compared to the prior year's comparable period, Stoke Therapeutics has seen an increase in its net loss for both the three-month ($48.2M vs $44.1M) and six-month ($95.5M vs $86.5M) periods ending June 30, 2025. This widening loss is primarily driven by increased Research and Development expenses, which rose to $40.5M in Q2 2025 from $36.6M in Q2 2024, reflecting higher external program costs. General and administrative expenses also saw a modest increase. The company's cash position has decreased, indicating a higher burn rate, while revenue remains at $0, consistent with its pre-commercial status.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share STOK Nasdaq Glo
• $700.0 million — ck held by non-affiliates was less than $700.0 million and its annual revenue is less than $10
• $100.0 million — ion and its annual revenue is less than $100.0 million as of the last business day of its most
• $250.0 million — ock held by non-affiliates is less than $250.0 million or (ii) its annual revenue is less than

Filing Documents

• stok-20250630.htm (10-Q) — 2523KB
• stok-ex10_1.htm (EX-10.1) — 102KB
• stok-ex10_2.htm (EX-10.2) — 47KB
• stok-ex10_3.htm (EX-10.3) — 46KB
• stok-ex31_1.htm (EX-31.1) — 17KB
• stok-ex31_2.htm (EX-31.2) — 17KB
• stok-ex32_1.htm (EX-32.1) — 9KB
• stok-ex32_2.htm (EX-32.2) — 10KB
• img146265908_0.jpg (GRAPHIC) — 105KB
• img146265908_1.jpg (GRAPHIC) — 58KB
• 0000950170-25-107332.txt ( ) — 9264KB
• stok-20250630.xsd (EX-101.SCH) — 882KB
• stok-20250630_htm.xml (XML) — 1611KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 5 Consolidated balance sheets 5 Consolidated statements of operations and comprehensive income (loss) 6 Consolidated statements of stockholders' equity 7 Consolidated statements of cash flows 8 Notes to unaudited consolidated financial statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 34 PART II. OTHER INFORMATION 35 Item 1.

Legal Proceedings

Legal Proceedings 35 Item 1A.

Risk Factors

Risk Factors 35 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 73 Item 3. Defaults Upon Senior Securities 73 Item 4. Mine Safety Disclosures 73 Item 5. Other Information 73 Item 6. Exhibits 74

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of present and historical facts contained in this Quarterly Report on Form 10-Q, including, but not limited to, statements regarding the receipt of upfront payments, potential milestone or royalty payments or the exercise of options under our collaboration with Biogen International GmbH ("Biogen"), the ability of zorevunersen (STK-001) to treat the underlying causes of Dravet syndrome and reduce seizures or show improvements in behavior or cognition at the indicated dosing levels or at all, the timing and expected progress of clinical trials, our future results of operations and financial position, business strategy, prospective products, planned preclinical studies and clinical or field trials, regulatory approvals, research and development costs, and timing and likelihood of success, as well as plans and objectives of management for future operations, may be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to va

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. Stoke Therapeutics, Inc. and subsidiary Consolidated ba lance sheets (in thousands, except share and per share amounts) (unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 101,472 $ 127,983 Marketable securities - current 146,236 88,916 Prepaid expenses 13,694 11,117 Restricted cash - current 75 75 Interest receivable 1,622 700 Other current assets 6,871 3,965 Total current assets $ 269,970 $ 232,756 Marketable securities - long-term 107,256 29,824 Restricted cash - long-term 721 721 Operating lease right-of-use assets 3,218 4,345 Property and equipment, net 3,343 3,909 Total assets $ 384,508 $ 271,555 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 4,313 $ 2,498 Accrued and other current liabilities 25,616 18,567 Deferred revenue - current portion 8,749 18,991 Total current liabilities $ 38,678 $ 40,056 Deferred revenue - net of current portion 9,632 — Other long term liabilities 1,255 2,478 Total long term liabilities 10,887 2,478 Total liabilities $ 49,565 $ 42,534 Commitments and contingencies (Note 6) Stockholders' equity Common stock, par value of $ 0.0001 per share; 300,000,000 shares authorized, 54,723,455 and 54,032,826 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 5 5 Additional paid-in capital 736,276 719,997 Accumulated other comprehensive income (loss) 96 ( 151 ) Accumulated deficit ( 401,434 ) ( 490,830 ) Total stockholders' equity $ 334,943 $ 229,021 Total liabilities and stockholders' equity $ 384,508 $ 271,555 The accompanying notes are an integral part of these unaudited consolidated financial statements. 5 Stoke Therapeutics, Inc. and subsidiary Consolidated stateme nts of operatio

View Full Filing

View this 10-Q filing on SEC EDGAR